PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Negative net income growth while GNPX stands at 24.80%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
5.37%
Less D&A growth vs. GNPX's 178.97%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
42.67%
Deferred tax of 42.67% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-15.52%
Both cut yoy SBC, with GNPX at -31.45%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
2.45%
Less working capital growth vs. GNPX's 30.63%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Negative yoy AP while GNPX is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
389.89%
Growth well above GNPX's 26.33%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-15.52%
Negative yoy while GNPX is 27.04%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.74%
Negative yoy CFO while GNPX is 23.49%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
51.76%
Some CapEx rise while GNPX is negative at -30.21%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while GNPX stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
We have some outflow growth while GNPX is negative at -59.66%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
253.33%
We have mild expansions while GNPX is negative at -30.21%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
100.00%
Debt repayment growth of 100.00% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-79.28%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.